Drug intelligence / Profile preview

VV-969

Development stage: Preclinical
Lead developer: Vivat Therapeutics
Modality: Small Molecules

Overview

VV-969 is a small-molecule ferroptosis inhibitor being developed as a disease-modifying therapy for age-related diseases, with an initial focus on sarcopenia. Originally developed by Collaborative Medicinal Development (which rebranded as Vivat Therapeutics), the compound is designed to inhibit ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation. Preclinical development is ongoing to evaluate its potential in treating muscle loss and other age-related degenerative conditions.

Targets

TOP1 (DNA Topoisomerase I)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)

Beyond the preview

Go deeper on VV-969.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VV-969.

Explore the full profile